Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BIA202202

CD19 mAb

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: CD19 mAb
    Indications: Autoimmune diseases/ B cell malignancies
    Research phase: Apply for IND
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.

    (1) CD19 is expressed on normal B cells, but it is not found on hematopoietic stem cells, and other healthy tissues.

    (2) CD19 is expressed on nearly all B-cell malignancies: including ALL, CLL, many NHL (>95%).

    (3) Long-lived plasma cells produce autoantibodies, lack CD20 but majority express CD19.


    Clin Cancer Res. 2011

    (Clin Cancer Res. 2011;17(20):6448-6458. doi:10.1158/1078-0432.CCR-11-0485)


    2. High affinity with native CD19 antigen on cell surface.


    High affinity with native CD19 antigen on cell surface


    3. Cross binding with Cyno (but low affinity).


    4. High efficacy of anti-cancer and reversing autoimmune disease in-vitro and in-vivo.


    High efficacy of anti-cancer and reversing autoimmune disease in-vitro and in-vivo


    5. High stability and good drug ability.


    High stability and good drug ability



  • Project Introduction

    1. Asset type: CD19 mAb

    2. Modality: ADCP, CDC maintained, and ADCC enhanced fully human antibody

    3. Indication: Autoimmune diseases/ B cell malignancies

    4. Research phase: Apply for IND

    5. Research progress:
       1. Cell bank construction finished.
       2. Preparation development and purification method development have been completed.
       3. The in vivo and in vitro antitumor efficacy of CD19 mAb is comparable to the Uplizna and Monjuvi.
       4. CD19 mAb and Uplizna showed similar efficiency in reversing autoimmune disease.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message